Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has provided an announcement.
Zai Lab Limited has scheduled a board meeting for February 26, 2026 to consider and approve its audited financial results for the year ended December 31, 2025, prepared under U.S. GAAP and U.S. SEC requirements. If approved, the company will publish the 2025 annual results on the Hong Kong exchange website and its own investor relations site the same day.
Following the release, Zai Lab’s management will host a teleconference and webcast on February 26, 2026 to discuss the results and take questions from the investment community. The company also plans to issue its Hong Kong-compliant annual results announcement by March 31, 2026, including a reconciliation from U.S. GAAP to IFRS, underscoring its commitment to transparency for cross-border shareholders.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company listed in Hong Kong that develops and commercializes innovative medicines, with its financial reporting prepared under U.S. GAAP and subject to U.S. SEC rules. The company is also subject to Hong Kong Listing Rules, reflecting its dual-market regulatory and investor base across the U.S. and Hong Kong markets.
Average Trading Volume: 10,552,263
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.26B
Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page.